\ on=	DesKtop\::ODMA/MHODMA/	330768;1				Sheet 1 of 1	
E49 10 W		ATTORNEY DOCKET NO. 1802.1004-001		APPLICATION NO. 09/988,496		TECH	
G DOL THEORMAT	SUPPLEMENTAL ON DISCLOSURE CITATION AN APPLICATION	APPLICANT David J. Ar	nderson, et	al.		TECH CENTER 1600/28	
FLOT & TRADES	August 2, 2002 eral sheets if necessary)	FILING DATE November 20	0, 2001	GROUP 1614		-R 1600	
		S. PATENT DOCT	iments				
IAM- IER II-	DOCUMENT NUMBER	DA	TE	NAME	SUB- CLASS	FILING IF APPROPRIATE	
<u></u>				-			
	POF	RBIGN PATENT DO	CUMENTS				
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO	
4.1.4	EP 0 999 278 A1	10 MAY 00	EPO		 		
AO AO	WO 00/30673	02 JUN 00	PCT				
AQ					<u> </u>		
			_				
							
EXAMINE	< 101 Valler	DATE CONSI	IDERED 7	22/	05		



Appli**či**nts:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

David J. Anderson, Guillermo Garcia-Cardena, Michael A. Gimbrone,

Hai U. Wang

Application No.:

09/988,496

Group:

1614

X

Filed:

November 20, 2001

Examiner:

Unknown

For:

ARTERY SMOOTH MUSCLE- AND VEIN SMOOTH MUSCLE-SPECIFIC

PROTEINS AND USES THEREFOR

CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, P.O. Box 2327, Arlington, VA 22202 Date Signature Linda M. Amato Typed or printed name of person signing certificate

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents P.O. Box 2327 Arlington, VA 22202

(Filed after payment of issue fee)

\sim	٠		
•	1	•	•
. 7		и	١.

	,···, ··· =====
Sir:	
This I	Information Disclosure Statement is submitted: under 37 CFR 1.129(a), or (First/Second submission after Final Rejection)
[X]	under 37 CFR 1.97(b), or (Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).
[]	under 37 CFR 1.97(c) together with either: [] a Statement under 37 CFR 1.97(e), as checked below, or [] a \$180.00 fee under 37 CFR 1.17(p), or (After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
[]	under 37 CFR 1.97(d) together with: [] a Statement under 37 CFR 1.97(e), as checked below, and [] a \$180.00 fee under 37 CFR 1.17(p), or (Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)
[]	under 37 CFR 1.97(i): Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.

Staten	ent Un	der 37 C	FR 1.97(e)			
[]	Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or					
[]	knowle in the	No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.				
Statem	ent Un	<u>der 37 Cl</u>	(Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 200			
[]	commi	unication ot receive	formation contained in the Information Disclosure Statement was cited in a from a foreign patent office in a counterpart application and this communication d by any individual designated in § 1.56(c) more than thirty days prior to the ormation Disclosure Statement.			
[X]	Enclos	sed herew	rith is form PTO-1449:			
	[X]	Copy of	cited references AO and AP are enclosed.			
	[]	Applica	of cited references are enclosed except those entered in prior application, U.S. tion No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier ion contains copies of the cited references.]			
•	[X]	The list counterp	ed reference AO was cited in the enclosed International Search Report in a part foreign application.			
	[]	The "co under 3"	ncise explanation" requirement (non-English references) for reference(s) []7 CFR 1.98(a)(3) is satisfied by:			
		[] 1	he explanation provided on the attached sheet.			
		[] 1	he explanation provided in the Specification.			
		[]	submission of the enclosed International Search Report.			
		[]	submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.			
		[] 1	he enclosed English language abstract.			

[X]	Applio	cant requests that the following non-published pending applications be considered:
Examiner's Initials		
		U.S. Patent Application No. 09/085,820, by Hai U. Wang, Zhoufeng Chen and David J. Anderson, filed May 28, 1998, Docket No.: 1802.1003-002.
		U.S. Patent Application No. 09/687,652, by Hai U. Wang, Zhoufeng Chen and David J. Anderson, filed October 13, 2000, Docket No.: 1802.1003-009.
		U.S. Patent Application No. 09/823,009, by Hai U. Wang, Zhoufeng Chen and David J. Anderson, filed March 30, 2001, Docket No.: 1802.1003-011.
		Examiner Date
	[X]	A copy of each above-cited application, including the current claims, is enclosed.
	[]	A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.
The Ex	kaminer ices wei	is requested to return a copy of the above list of pending applications indicating which re considered with the next office communication.
It is re	quested	that the information disclosed herein be made of record in this application.
Metho	d of pay	ment:
[]		ck for the fee noted above is enclosed, or the fee has been included in the check with the panying Reply. A copy of this Statement is enclosed.
[]	Please	charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is ed.
[X]	Please	charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.
		Respectfully submitted,
		HAMILTON, BROOK, SMITH & REYNOLDS, P.C.
		By Line Claig Anne I. Craig Registration No.: 32,976 Telephone: (978) 341-0036 Facsimile: (978) 341-0136

Concord, MA 01742-9133 Dated: 8/2602

ID NO.: ::ODMA\MHODMA\IManage; 28886\:1 Sheet 1 of 4								
PTO-1449 REPRODUCED MAR 0 7 2002			ATTORNEY DOCKET NO. 1802.1004-001	APPLICATION NO. 09/988,496				
	NF	ORMATION DISCLOSURE CITATION IN AN APPLICATION TRADEMIN	APPLICANT David J. Anderson, et al.					
	(Us	March 4, 2002 se several sheets if necessary)	FILING DATE November 20, 2001	GROUP 1614				
<u> </u>		U.S.	PATENT DOCUMENTS					
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	AME SUB- FILING DA' CLASS IF APPROPRIA		IF	
	AA							
	. AB		1					
	<u> </u>	FOREIG	N PATENT DOCUMENTS					
	ļ	DOCUMENT NUMBER	DATE	CLASS	SUB- CLASS	TRANS YES	LATION NO	
4	X AL	WO 96/26958	27 FEB 96	PCT				
1	AM	WO 99/52541	21 OCT 99	PCT				
	AN	0 633 315 A2	11 JAN 95	EPO				
	AO							
	AP							
	AQ							
	т	OTHER DOCUMENTS (Including Aut						
10	AR	Bennett, B. D., et al., "Molecular Cloning of a Ligand for the EPH-Related Receptor Protein-Tyrosine Kinase Htk," Proc. Natl. Acad. Sci. USA, 92:1866-1870 (1995).						
	AS	Bergemann, A. D., et al., "ELF-2, a New Member of the Eph Ligand Family, Is Segmentally Expressed in Mouse Embryos in the Region of the Hindbrain and Newly Forming Somites," Mol. Cell Biol., 15(9):4921-4929 (1995).						
	АТ	Stein, E., et al., "Eph Receptors Discriminate Specific Ligand Oligomers to Determine Alternative Signaling Complexes, Attachment, and Assembly Responses," Genes Dev. 12:667-678 (1998).						
	AU	Andres, A-C., et al., "Expression of Two Novel Eph-Related Receptor Protein Tyrosine Kinases in Mammary Gland Development and Carcinogenesis," Oncogene, 9:1461-1467 (1994).						
	AV	Folkman, J., et al., "Blood Vessel Formation: What Is Its Molecular Basis?" Cell, 87:1153-1155 (1996).						
	AW	Risau, W., Mechanisms of Angiogenesis, "Nature, 386:671-674 (1997).						
	AX	Pasquale, E. B., "The Eph Family of Receptors," Curr. Opin. Cell. Biol. 9:608-615 (1997).						
	AY	Wang, H. U., et al., "Eph Family Transmembrane Ligands Can Mediate Repulsive Guidance of Trunk Neural Crest Migration and Motor Axon Outgrowth," Neuron, 18:383-396 (1997).						
	Asahara, T., et al., "Isolation of Putative Progenitor Endothelial Cells for Angiogenesis," Science, 275:964-967(1997).							
XAMIN			DATE CONSIDERED					
) (2/ L) (1/2/2)	7/22/4					

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, P.O. Box 2327, Arlington, VA 22202

on

Linda M Crawford

Typed or printed name of person signing certificate

INFORMATION DISCLOSURE STATEMENT

[] a \$180.00 fee under 37 CFR 1.17(p), or

(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)

[] under 37 CFR 1.97(d) together with:

[] a \$180.00 fee under 37 CFR 1.97(e), as checked below, and

[] a \$180.00 fee under 37 CFR 1.17(p), or

(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)

Assistant Commissioner for Patents

P.O. Box 2327

[] under 37 CFR 1.97(i):
Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.

(Filed after payment of issue fee)

[]

Statement Under 37 CFR 1.97(e) Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or [] No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement. Statement Under 37 CFR 1.704(d) (Patent Term Adjustment) Applies to original applications (other than design) filed on or after May 29, 2000 Each item of information contained in the Information Disclosure Statement was cited in a [] communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement. Enclosed herewith is form PTO-1449: [X]Copies of the cited references AL-AN, AR-AZ, AR2-AZ2, AR3-AZ3, AR4-AZ4 and [X]AR5-AZ5 are enclosed. Copies of cited references are enclosed except those entered in prior application, U.S. [] Application No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.] [.] The listed references were cited in the enclosed International Search Report in a counterpart foreign application. The "concise explanation" requirement (non-English references) for reference(s) under 37 CFR 1.98(a)(3) is satisfied by: the explanation provided on the attached sheet. [] the explanation provided in the Specification. submission of the enclosed International Search Report.

submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.

the enclosed English language abstract.

[]	Ap	plicant requests that the following I	non-published pending appli	cations be considered:			
Examiner's Initials	i						
111111111		U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []			
		U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []			
		U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []			
		Examiner	Date	-			
		,		·			
	[]	A copy of each above-cited app	plication, including the curre	ent claims, is enclosed.			
	[]	A copy of each above-cited app those entered in prior application 35 U.S.C. 120 is claimed.	plication, including the curre on, U.S. Application No. [ent claims, is enclosed, exception], to which priority under			
The E	xam:	iner is requested to return a copy of were considered with the next office	the above list of pending ap ce communication.	plications indicating which			
It is re	ques	sted that the information disclosed h	nerein be made of record in t	his application.			
Metho	d of	payment:		·			
[]	A c	check for the fee noted above is encompanying Reply. A copy of this S	losed, or the fee has been inc Statement is enclosed.	cluded in the check with the			
[]		the charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is used.					
[X]	Ple	ase charge any deficiency in fees ar	nd credit any overpayment to	Deposit Account 08-0380.			
		I	Respectfully submitted,				
		I	HAMILTON, BROOK, SMI	TH & REYNOLDS, P.C.			
		1	By MM May Anne I. Craig	· 			
			Registration No.: 32,976 Telephone: (978) 341-0036	5			
			Facsimile: (978) 341-0136)			

Concord, MA 01742-9133 Dated: 3/4/02